InspireMD Inc (NSPR) has disclosed a new risk, in the Capital Markets category.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
InspireMD Inc. faces significant business risks due to potential changes in trade policies, including tariffs and customs regulations, which could adversely impact its reputation, financial condition, and operational results. The company’s reliance on manufacturing and distributing its CGuard Prime carotid stent system from Israel to the U.S. market makes it vulnerable to any new tariffs or changes in trade agreements between the two countries. Such developments could lead to increased costs, affecting gross margins and pricing flexibility, while also introducing logistical challenges and supply chain modifications. These trade-related risks underscore the importance of InspireMD’s ongoing efforts to establish manufacturing operations in the United States with Aptyx Interventional Systems.
The average NSPR stock price target is $4.50, implying 83.67% upside potential.
To learn more about InspireMD Inc’s risk factors, click here.